- NAVIFY® Oncology Hub provides a central workspace for clinicians to quickly access relevant patient data to optimise care decisions and enhance care coordination
- NAVIFY® Oncology Hub securely aggregates and organises patient data from disparate sources, providing a longitudinal view of the patient’s cancer care journey
- New digital solution streamlines clinical workflows and reduces administrative burden on clinicians, allowing oncologists to spend less time on patient records, and more time with patients
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of NAVIFY® Oncology Hub, its latest digital solution to further enhance clinical decision support and workflow optimisation for oncologists and oncology care teams.
Oncologists often face incomplete patient records and data silos across multiple IT systems. This makes it difficult to find and collect all relevant data to get the full picture of the patient’s health history and assess each case holistically. These workflow inefficiencies can also create significant administrative, operational and financial burden.
NAVIFY® Oncology Hub addresses these challenges by securely aggregating and organising fragmented patient data across an institution’s IT systems. It simplifies day-to-day workflows for oncology care teams and serves as a central workspace where the most relevant patient data can easily be found, accessed and reviewed by all members of the team. NAVIFY® Oncology Hub presents the information as a longitudinal timeline view of the patient’s full oncologic history, combined with a concise snapshot of the individual’s current status. With it, clinicians can efficiently prepare for patient consultations, quickly and concisely convey information and coordinate care across the team. NAVIFY® Oncology Hub also helps facilitate discussions between oncologists and patients about complex treatment options and next steps.
“Clinicians are under enormous pressure to navigate complex workflows and consider all the relevant information to decide on the best possible care option for each patient in a timely fashion", says Moritz Hartmann, Global Head of Roche Information Solutions. “With our digital solutions, we can empower healthcare professionals and patients to make personalised, insights-based decisions across the patient care continuum - helping improve outcomes, and reduce costs to society.”
NAVIFY® Oncology Hub, the latest addition to the NAVIFY® Decision Support portfolio, will be initially available in the US, Germany and Taiwan before being rolled out to additional markets in the near future.
About NAVIFY® Decision Support portfolio
NAVIFY® Decision Support portfolio is a portfolio of interoperable, scalable workflow products and clinical decision support solutions that empower personalized healthcare. By aggregating patient-specific information with relevant, curated scientific and medical data from an ever-expanding knowledge base, clinicians can confidently make more personalized, timely decisions – fundamentally changing the way diseases are managed across the care continuum. For more information, please visit www.navify.com/products
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.